Prince William and Prince Harry have each paid a tribute to Princess Diana, though not side by side. Both brothers backed their late mother's charity with personal messages to the winners of The Diana Award, while also extending her legacy through the causes they champion. Their separate letters, however, say plenty about the ongoing feud between the two.
According to People, the Prince of Wales, 44, and the Duke of Sussex, 42, wrote congratulatory letters to the newest winners of The Diana Award. The letters, however, went out separately. Each of the 198 recipients, drawn from 44 countries, received one from each prince.
According to the charity, the winners were recognised for creating "positive change in their communities and beyond." Dr. Tessy Ojo CBE, the charity's chief executive, also praised the group. "These young people are proof that, whatever their background or circumstances, the desire to make a difference is universal," she said.
However, reports from Page Six suggest that the common gesture does not appear to signal a thaw. The brothers last appeared together at a public engagement in July 2021, when they unveiled a statue of Diana at Kensington Palace on what would have been her 60th birthday. Since then, they have seemed distant at Queen Elizabeth II's funeral and at a 2024 memorial service for their uncle.
While they are now in the same country again, they are not believed to be in contact. Harry has spoken about the rift. "I want it to work out. Of course I do," he said, while also admitting that reconciling is hard. The escalation of tensions can be traced to 2020, when Harry and Meghan Markle stepped down as senior working royals.

#prince #according #people #side

Pat McAfee did not enjoy his time in Utah last weekend as "College GameDay" was in Salt Lake City for the Utes' win over the Houston Cougars. The day before the broadcast the college shared a social media post with students saying things about McAfee that made him fear for his safety and alluded to the ****** assination of Charlie Kirk. He later said that he was advised to wear a bulletproof vest.
One person who does not feel any sympathy for McAfee is Michelle Beadle, the former ESPN personality who currently hosts "Run It Back" on FanDuel TV. Beadle appeared on Thursday's episode of "The Dan Le Batard Show" and was asked to weigh in on McAfee's week.
Beadle made the case that no woman in media could be as "soft" as McAfee and insisted that she was "enjoying every single second" of the fallout this week.
MORE: Pat McAfee 'always paranoid,' had Barstool co-workers 'walking on eggshells'
"Just want to remind all your viewers, your listeners, everyone who is fans of you guys… We are constantly told as women that we're hysterical, we're too emotional, we can't handle things," said Beadle. "I can't tell you how many death and rape threats I've gotten via social media in the last, I don't know, since 2009 when we got on Twitter originally. I could never be that soft. Never. This has been one of the softest, and we've seen quite a few from some of the people at the top of this food pyramid of sports media… one of the softest reactions to something that was so ridiculously unserious."

#mcafee #beadle #last #Social

I'm living proof of the saying that "kids keep you young." My wife and I don't need social media. We've got multiple social barometers living in our house. But my usual reaction to every new trend or slang that enters their lexicon ("cooked" and "tuff" have been the new favorites) is skepticism. Before I try to figure out how much attention I need to put into what has them hyped, I try to figure out how serious they are about their enthusiasm.
Sunday's fantasy football action left me in a similar spot. We didn't get many massive box score performances from our stars. Instead, Week 6 was about our mid- and late-round picks or waiver-wire acquisitions. And with some giving us repeat results, the storylines coming out of Sunday should have us adjusting how we approach fantasy free agency on Tuesday.
Both Trevor Lawrence and C.J. Stroud were hooping all morning. They were the perfect pivot from whatever we had to watch on TNF. But as I was watching the Texans offense, a couple of things stood out.
what a throw from Stroud, too. pic.twitter.com/fz4EbOAKvT https://t.co/2MaTqWpPgd
First, Stroud's command of the offense was at an all-time high. Jacksonville came into the game with the 12th-highest pressure rate. Houston had a twofold response. It used an extra lineman on 35.6% of its plays (a season-high), and Stroud was getting rid of the football in 2.31 seconds (a season-low). The result was not only his lowest pressure rate (8.6%) but also his highest EPA per dropback (0.35). More importantly, the Jaguars' defensive measures, which included blitzing Stroud on 31.4% of his dropbacks, didn't stop him from throwing the ball.

#fantasy

If Harper Beckham has no fans, it's because her elder brother, Cruz Beckham, has perished.
The budding musician had a fabulous reaction to his younger sister and budding beauty mogul, who was the topic of a conversation between British presenter Holly Willoughby and The Traitor's star, Joanne McNally.
The Irish comedian was asked by the former This Morning host which celebrity she would like to be, to which Joanne replied: "Harper Beckham," adding that she knew it "should be someone like Tina Fey."
Joanne went on to cite all the things she felt would be brilliant about being the 15-year-old, having the influence of Victoria Beckham, her upcoming beauty brand, as well as holidaying on a yacht, all being things on Joanne's list.
And the proof was in the pudding, as Cruz left a gushing comment on a clip of the moment on TikTok. "Me too, Harper is the most amazing human ever," which gained 1,239 likes.

#beckham #joanne #cruz #british

Kate Middleton showed that green is one of her go-to colors for fall. While visiting the Royal Marsden NHS Foundation Trust in London, England, on September 11, 2026, the Princess of Wales arrived in a green apple midi dress by the British brand Suzannah London. The silk dress, known as the Flippy Wiggle Dress, featured black ****** ons running down the front with a tonal belt and short, capped sleeves. The dress was a re-wear for the royal; she first stepped out in the frock on May 18, 2023, while visiting the Anna Freud Centre in London. She likes that particular dress style so much that she also stepped out in a white version of the Flippy Wiggle dress with black detailing in July 2026. The white dress was Middleton's summer choice, while the green apple version is better suited to fall.
The hospital visit was a deeply personal one for the princess; Middleton received cancer treatment at the Royal Marsden Hospital in 2024, and so her visit during fall 2026 was an opportunity to connect with current patients and hospital staff. While it was obviously a very meaningful visit, it was also fitting that she chose to wear a green dress. In fashion, green symbolizes hope and new life, so her dress was a gesture of goodwill toward those in recovery.
Read more: Pamela Anderson & Kate Middleton Love The 'No-Manicure Manicure' Right Now
Wpa Pool/Getty
Kate Middleton has become an undisputed muse of fall fashion, and her enviable wardrobe provides endlessfall outfit inspo, featuring green as her signature color for the season. She wore the green apple Suzannah London dress on September 11, 2026, as proof. A few days earlier, on September 8, 2026, the princess wore a green Emilia Wickstead dress when she and Prince William dropped off Prince George for his first day at the elite boarding school, Eton College. It seems she's all about green for these meaningful events.

#green #september #hospital

Is there any investment market segment more debated than gold (XAUUSD)? I'm not sure there is. We have "gold bugs," including those who see the yellow metal as the ***** et to own when the world goes haywire.
Then, there are the "we're going back on the gold standard" types. The ones that preceded crypto bros in believing fiat currencies weren't for this world. It follows that gold would return to its former role as the reserve currency.
Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market ***** ysis you won't find anywhere else.
Of course, there are also plenty of investors who don't really think about gold investing very much, and who will simply trade it when there's a good opportunity. I'm in this camp.
Financial media pundits routinely tout gold as some sort of bulletproof allocation. Inflation worries? Own gold. Currency debasement? Own gold. Want your kitchen to be decorated like the Oval Office? You'll need a lot of gold.

#Gold #free #barchart #brief

Merck (MRK) stock returned about 87% over the past twelve months, climbing from roughly $79 to about $147. Nothing in the year's results looks like that. The medicines Merck sells today grew at their usual pace. Investors spent the year repricing what comes next.
Revenue over the trailing twelve months was $66.6 billion, up 4.6% and in line with its own three-year pace. Profitability did not follow. Its operating margin over the same twelve months was 10.5%, versus a three-year average of 22.4%.
Most of that gap is one purchase. Merck took a $5.7 billion charge in the second quarter of 2026, about 9% of a year's sales. It bought Terns Pharmaceuticals, and with it MK-4208, a candidate for chronic myeloid leukemia. The bill hits earnings now and the medicine arrives later.
The proof matters because of the risk hanging over this stock. The KEYTRUDA family was just over half of Merck's revenue in the second quarter of 2026. The company is openly planning for the end of that exclusivity when Keytruda loses primary U.S. patent protection in 2028. Management describes the stretch as more of a hill than a cliff, with a shallow dip and a fast return to growth.
Johnson & Johnson (JNJ) returned 56% over the same twelve months and Pfizer (PFE) 23%, so a good year for pharmaceuticals explains some of this but not Merck's lead. What separated Merck was evidence. The FDA approved LIPFENDRA, the first and only oral PCSK9 inhibitor. In the CORALreef Lipids trial it lowered LDL cholesterol by up to 60% when added to a statin.

#year #johnson

Charles Schwab is holding a neutral stance on equities. The firm favors commodities over stocks and bonds, according to chief investment strategist Liz Ann Sonders.
Sonders made the comments in a recent interview, pushing back on what she called "cookie-cutter" portfolio advice. She said allocation should hinge on each investor's time horizon, risk tolerance, need for income, and overall goals.
"It actually drives me a little crazy when people give a cookie-cutter answer to that," Sonders said. "There's no one ***** et allocation that makes sense right now."
https://www.youtube.com/wa...
Schwab oversees $13.4 trillion in client ***** ets, and Sonders pointed to that scale as proof there is no single right answer for every client.

#sonders #cutter #answer #h5jfl8lawe

Concerned about an AI bubble? Sign up for The Daily Upside for smart and actionable market news, built for investors.
Let's just come right out and say it: It's a good time to sell a registered investment advisor practice.
We've all read headlines about sky-high multiples and firm owners fielding multiple calls a day from potential suitors. It's an environment where successful founders can generate tremendous value from selling their firms. The process isn't simple, however, and there are pitfalls that owners can stumble into, potentially robbing them of hard-earned enterprise value.
Adam Lewis, partner at Vedder Price, talked through these dynamics this week during a standing-room only session at the Future Proof Festival in Huntington Beach, California. While he advises on M&A across multiple industries, the world of wealth management stands apart in 2026 as the "strongest by far" in terms of dealmaking activity. The entrance of private equity buyers in the RIA **** e has been particularly significant, with the heightened competition among buyers helping ramp up valuations. It's a great environment for sellers who hope to monetize their life's work to fund their retirement lifestyle and potentially create intergenerational wealth, Lewis said. But it's important to be diligent and bring the right expertise to the table during the negotiation process.
Sign up for The Daily Upside at no cost for premium **** ysis on all your favorite stocks.

#lewis

On September 15, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) completed its acquisition of privately held Actio Biosciences for $820 million upfront, adding a clinical-stage epilepsy drug called ABS-1230 to its rare disease pipeline. The deal lands weeks after Jazz posted its highest quarterly revenue ever on August 3, and raised its full-year guidance, so a fresh acquisition now sits on top of a business that was already accelerating. The question for investors is whether that combination adds up to durable growth or just a bigger bill.
ABS-1230 targets KCNT1-related epilepsy, a rare and hard-to-treat form of the disease. In an early clinical proof-of-concept trial, children who received the drug experienced meaningful seizure reductions, and preclinical testing showed it inhibited KCNT1 across every pathogenic mutation researchers evaluated, hinting it could work across the whole patient population rather than a narrow subset. The FDA has already granted ABS-1230 Orphan Drug, Rare Pediatric Disease and Fast Track designations, and accepted it into the agency's Rare Disease Evidence Principles process, a set of regulatory advantages that can speed a drug toward approval.
The acquisition also arrives while Jazz's existing business is firing on multiple cylinders. Second-quarter revenue climbed 16% year over year to $1.2 billion, the company's highest quarterly total on record, and management raised full-year 2026 revenue guidance to a range of $4.6 billion to $4.75 billion. Growth was not confined to one product. Xywav sales rose 13% to $471 million on 525 net new patients, Epidiolex grew 16% to $292 million, and Zepzelca jumped 42% to $106 million. Zanidatamab, sold as Ziihera in biliary tract cancer, also received Breakthrough Therapy designation from the FDA for a form of colorectal cancer, adding another avenue for the oncology franchise Jazz has been building beyond its epilepsy and sleep businesses.
None of that came free. The $820 million upfront payment for Actio lands on top of $4.4 billion in long-term debt that Jazz already carried as of June 30, even after the company used part of its cash to repay $1.0 billion of exchangeable notes that matured this year. Cash, equivalents and investments stood at $2.2 billion at that point, meaning the Actio payment alone accounts for a meaningful share of the company's liquid resources.
Jazz's recent history also shows how acquisitions can distort the bottom line before they pay off. A $905.4 million in-process research and development charge tied to the 2025 Chimerix acquisition pushed second-quarter 2025 GAAP earnings to a loss of $11.74 per share, and a smaller $77 million IPR&D charge from the AbCellera and Werewolf deals still dented second-quarter 2026 results. ABS-1230 itself remains early, with only proof-of-concept data in hand and no late-stage trial results yet. The portfolio is not without setbacks, either. Jazz is moving to voluntarily drop the second-line indication for Zepzelca in meta

Ethereum runs smart contracts on a proof-of-stake network where over a third of circulating ETH is staked, earning low single-digit yields.
Over five years, Bitcoin gained 58% while Ethereum lost 30%, exposing a stark performance gap despite Ethereum's expanding platform usage.
Spot Ethereum ETFs exclude staking yield, and IRS tax uncertainty on staking rewards continues to limit institutional capital from participating.
Just released. Our ***** ysts combed the entire stock market and named the ten best stocks to buy right now. The report is free. Enter your email and see if any of your stocks made the cut.
Ethereum (CRYPTO:ETH) is a blockchain built to run programs, which is why people point to it when they say crypto can do more than move money. Developers deploy code to it, users call that code, and the network's native token, ETH, pays for the computing power behind every transaction.

#ethereum #Crypto #stocks #enter

He was the sole holdout on a 12-person jury who otherwise voted to acquit Lindsay Clancy of murdering her three children — frustrating the defense and causing a mistrial.
After seven days of deliberations, and with specific instructions from Judge William Sullivan to follow the letter of the law on reasonable doubt, the jury said it still had one holdout who refused to budge. A mistrial was declared on Sept. 4.
Now, the lone juror, named Michael Desronvil, has come forward to share his side of the story, saying that he "didn't have any doubts" that Clancy was criminally responsible for the killings.
In a statement shared with Yahoo on Sept. 18 by his attorney Edward Andrew Paltzik, Desronvil said: "I didn't have any doubts. As I tried to explain different possible theories during deliberation, I kept getting cut off as if I had doubts based on the evidence presented.
"Based on all the physical evidence, key witnesses, and what the prosecution presented, I thought it was enough proof that she (Clancy) knew exactly what she was doing and planned."

#clancy #evidence

Bain Capital Ventures closed its 11th flagship fund at $1.6 billion on Wednesday, betting big on a "post-AGI world" that places AI agents as the chief economic driver of productivity.
The firm has been swapping software for something venture capital has never underwritten: AI-native companies that sell the work itself rather than the technology behind it.
Software startups made up 80% of Fund IX and around 20% of Fund X, said partner Matt Harris. For Fund X, AI-native startups made up 80% of the portfolio.
"The classic software startup is just not being born anymore," Harris said. "These companies where AI is just one feature among many, I think that's thoroughly uninteresting to us and, most importantly, to the most ambitious founders."
BCV defines "post-AGI" as AI agents being as productive as humans. This model's first proof point came in the form of Reserv, an AI-native insurance claims administration startup that the firm incubated with Altai Ventures and other partners. According to Harris, the company hit $100 million in revenue in its second full year. In May, the company raised a $125 million Series C.

#agents

VICTORIA, SEYCHELLES, September 16th, 2026, Chainwire
Bitget has published its August 2026 Proof of Reserves report, marking the 45th consecutive monthly disclosure since the program began in December 2022, with a total reserve ratio of 122% for the month. Separately, Bitget's August 2026 Protection Fund valuation report recorded an average monthly value of $382 million, backed by 5,500 BTC held as a separate protection reserve.
Bitget publishes both monthly Proof of Reserves and monthly Protection Fund valuation reports — two separate disclosures providing visibility into different parts of the platform's **** et-protection framework. The August PoR reserve ratio of 122% means Bitget's reported reserves for tracked **** ets exceeded the corresponding user balances included in the snapshot. A full per-asset breakdown is available on Bitget's Proof of Reserves page.
A reserve ratio above 100% reflects the position captured in a particular reporting snapshot and should not be interpreted as a financial audit or a guarantee of future solvency.
The Protection Fund's August valuation ranged from approximately $345.3 million on Aug 1, 2026 to $441.5 million on Aug 27, 2026, with an average monthly valuation of $382 million. Its dollar value fluctuates with Bitcoin's market price because the fund is backed by 5,500 BTC. Bitget established the fund in 2022 with an initial $300 million commitment, and its valuation remained above that level throughout August.

#proof

York Water holds the longest dividend streak in US public markets at 27 consecutive years, while WTW's $1.775B operating cash flow dwarfs its $358M dividend obligation.
Amdocs and Ituran both run near-recession-proof revenue models, with DOX posting near-100% managed services renewal rates and ITRN carrying zero debt alongside $103.7M in net cash.
All five stocks fund dividends from contracted or recurring revenue streams such as regulated rates, fee income, or subscriptions, insulating payouts from economic cycles.
Read More: Learn 7 secret wealth tips high net worth investors use that most investors miss (sponsor)
Income investors heading into the fourth quarter want payouts that don't wobble with the business cycle. The five names below share one thing: dividends funded by recurring, contracted, or fee-based revenue streams that keep flowing whether or not the macro cooperates. Each has raised its payout recently, and each trades on Nasdaq. As a grounding data point, Willis Towers Watson (NASDAQ:WTW) alone generated $360 million of first-half free cash flow, roughly double the prior-year period, giving the broker ample room to keep funding both dividends and buybacks.

#revenue #NASDAQ #Dividend

BioNTech SE (NASDAQ:BNTX) reported that its investigational lung-cancer drug gotistobart produced a clinically meaningful overall-survival benefit in the Phase 3 PRESERVE-003 trial in patients with metastatic squamous non-small cell lung cancer whose disease had progressed after prior immunotherapy and chemotherapy. Reuters said gotistobart nearly doubled survival compared with standard-of-care chemotherapy, strengthening the case for the drug as a potential chemotherapy-free treatment in a population with significant unmet need.
The result builds on earlier Stage 1 data, where gotistobart reduced the risk of death by 54% versus docetaxel, with a hazard ratio of 0.46. Median overall survival was not yet reached for gotistobart versus 9.95 months for docetaxel, while the 12-month progression-free survival rate was 25.2% versus 0%. BioNTech is now awaiting the pivotal Stage 2 readout, making the latest result important not only for the drug's approval prospects but also for the credibility of BioNTech's broader transition from a COVID-vaccine company toward a multi-product oncology business.
The strongest bullish argument is that gotistobart now has repeated evidence of a meaningful survival advantage in a difficult-to-treat lung-cancer population. The earlier Stage 1 dataset showed 55.6% of patients alive in the gotistobart arm versus 23.8% with docetaxel, alongside a 54% reduction in the risk of death. The latest Phase 3 update reinforces that signal rather than introducing an entirely new hypothesis. If the pivotal Stage 2 data confirm the benefit, BioNTech SE (NASDAQ:BNTX) could have a differentiated therapy capable of competing on survival rather than simply response rates, potentially supporting meaningful pricing power and a commercially attractive oncology franchise.
The result also strengthens BioNTech's broader oncology strategy because gotistobart is one piece of a much larger pipeline rather than a standalone bet. BioNTech says it has 14 ongoing pivotal trials and more than 10 novel combination programs, while its lung-cancer strategy spans more than 16 ongoing clinical trials and five Phase 3 programs. Gotistobart's success therefore provides validation for the company's immuno-oncology capabilities, while other ****** ets such as pumitamig and antibody-drug conjugates advance toward additional indications. BioNTech has identified 17+ late-stage or pivotal readouts through 2030+, creating the possibility that a successful gotistobart launch becomes the first major commercial proof point in its planned transition to a multi-product oncology company.

#stage #survival

BioNTech SE (NASDAQ:BNTX) reported that its investigational lung-cancer drug gotistobart produced a clinically meaningful overall-survival benefit in the Phase 3 PRESERVE-003 trial in patients with metastatic squamous non-small cell lung cancer whose disease had progressed after prior immunotherapy and chemotherapy. Reuters said gotistobart nearly doubled survival compared with standard-of-care chemotherapy, strengthening the case for the drug as a potential chemotherapy-free treatment in a population with significant unmet need.
The result builds on earlier Stage 1 data, where gotistobart reduced the risk of death by 54% versus docetaxel, with a hazard ratio of 0.46. Median overall survival was not yet reached for gotistobart versus 9.95 months for docetaxel, while the 12-month progression-free survival rate was 25.2% versus 0%. BioNTech is now awaiting the pivotal Stage 2 readout, making the latest result important not only for the drug's approval prospects but also for the credibility of BioNTech's broader transition from a COVID-vaccine company toward a multi-product oncology business.
The strongest bullish argument is that gotistobart now has repeated evidence of a meaningful survival advantage in a difficult-to-treat lung-cancer population. The earlier Stage 1 dataset showed 55.6% of patients alive in the gotistobart arm versus 23.8% with docetaxel, alongside a 54% reduction in the risk of death. The latest Phase 3 update reinforces that signal rather than introducing an entirely new hypothesis. If the pivotal Stage 2 data confirm the benefit, BioNTech SE (NASDAQ:BNTX) could have a differentiated therapy capable of competing on survival rather than simply response rates, potentially supporting meaningful pricing power and a commercially attractive oncology franchise.
The result also strengthens BioNTech's broader oncology strategy because gotistobart is one piece of a much larger pipeline rather than a standalone bet. BioNTech says it has 14 ongoing pivotal trials and more than 10 novel combination programs, while its lung-cancer strategy spans more than 16 ongoing clinical trials and five Phase 3 programs. Gotistobart's success therefore provides validation for the company's immuno-oncology capabilities, while other ***** ets such as pumitamig and antibody-drug conjugates advance toward additional indications. BioNTech has identified 17+ late-stage or pivotal readouts through 2030+, creating the possibility that a successful gotistobart launch becomes the first major commercial proof point in its planned transition to a multi-product oncology company.

#biontech #survival

VICTORIA, SEYCHELLES, September 16th, 2026, Chainwire
Bitget has published its August 2026 Proof of Reserves report, marking the 45th consecutive monthly disclosure since the program began in December 2022, with a total reserve ratio of 122% for the month. Separately, Bitget's August 2026 Protection Fund valuation report recorded an average monthly value of $382 million, backed by 5,500 BTC held as a separate protection reserve.
Bitget publishes both monthly Proof of Reserves and monthly Protection Fund valuation reports — two separate disclosures providing visibility into different parts of the platform's ***** et-protection framework. The August PoR reserve ratio of 122% means Bitget's reported reserves for tracked ***** ets exceeded the corresponding user balances included in the snapshot. A full per-asset breakdown is available on Bitget's Proof of Reserves page.
A reserve ratio above 100% reflects the position captured in a particular reporting snapshot and should not be interpreted as a financial audit or a guarantee of future solvency.
The Protection Fund's August valuation ranged from approximately $345.3 million on Aug 1, 2026 to $441.5 million on Aug 27, 2026, with an average monthly valuation of $382 million. Its dollar value fluctuates with Bitcoin's market price because the fund is backed by 5,500 BTC. Bitget established the fund in 2022 with an initial $300 million commitment, and its valuation remained above that level throughout August.

#valuation

On September 14, Coda Octopus Group (NASDAQ:CODA) reported third-quarter fiscal 2026 results that quietly crossed a threshold the company had never reached in its public history: positive retained earnings, after years of operating at an accumulated deficit. Revenue rose 9.2% year over year to $7.7 million, and pretax income climbed 16% to $1.8 million, even as instability in the Middle East knocked down the marine technology unit that has long been the company's calling card. The reason the quarter held together anyway comes down to where the growth actually showed up.
Defense engineering revenue jumped 68.3% to $2.7 million during the quarter, and the momentum did not look like a one-time ****** p. Sustainment spares orders have already topped $2.4 million year to date, and one prime contractor customer's new multiyear repair and sustainment award has since fed additional subcontract work back to Coda Octopus. On the newer end of the business, the company's US defense engineering team is now supporting several prime contractors building rugged, deployable RF electronic warfare systems for unmanned platforms, helicopters, airborne pods, and ground vehicles.
The DAVID diving system added its own proof points. Coda Octopus has delivered 24 DAVID systems to the US Navy to date, including 16 untethered units earlier in the year, and the Navy's authorization for use ****** sment on that untethered system was completed during the year, clearing it for full operational deployment. Since the quarter closed, the Navy has placed about $1.4 million in additional orders covering tethered systems and DAVID Flex adoption, including four units bought specifically for diving school and academy training. A European navy that already bought in is also expected to firm up a procurement roadmap later this year, while the new Nano sonar is being tested by subsea robotics OEMs and research groups for next-generation autonomous platforms. All of that arrived alongside $31.7 million in cash, no debt, and a balance sheet management says can fund acquisitions.
None of that offsets what happened in marine technology, the segment that still generates the largest share of revenue. Marine tech sales fell 15.2% to $3.4 million as customer activity slowed across the Middle East and parts of Asia, and hardware revenue specifically dropped 17.8% to $2.3 million. Improved rental utilization, with rental revenue up 131.1%, cushioned the blow but did not reverse it, and management has tied the weakness directly to geopolitical conditions it cannot control.

#revenue #david

The energy landscape is evolving rapidly, and one company looking to disrupt the status quo and redefine the future of nuclear power is NuScale Power (NYSE: SMR). NuScale is the only small modular reactor (SMR) developer to receive a Standard Design Approval from the Nuclear Regulatory Commission.
On Sept. 1, NuScale achieved a major engineering breakthrough. In collaboration with MilleniTEK, it successfully fabricated specialized boron-oxide pellets, a critical component of NuScale's cutting-edge passive emergency cooling system.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
This engineering triumph is a major step toward making safe, meltdown-proof modular nuclear power a reality. It also helps NuScale move closer to commercial deployment. But does this make NuScale Power stock a buy? Let's dive into the details and what it means for the stock.
In traditional nuclear reactors, reactivity control during nonstandard events often relies on active mechanical insertion of control rods or on powered chemical injection pumps. NuScale's 77 MWe Small Modular Reactor (SMR) design relies on passive safety mechanisms.

#power

For much of the past year, the "AI trade" has been focused on infrastructure: processors, data centers, and cloud capacity. Snowflake Inc. (NYSE:SNOW)'s blowout quarter, which was reported after the market closed on September 2, provided something unique: clear evidence that AI is translating into real, incremental spending within software companies that are closer to the end customer. The reaction echoed throughout corporate software the next morning, adding to a rally that, for Salesforce, Inc. (NYSE:CRM) in particular, had already begun for its own reasons.
Snowflake Inc. (NYSE:SNOW) boosted its fiscal 2027 product revenues target to $6.07 billion from $5.84 billion, following a 37% increase in second-quarter product revenue to $1.49 billion. CEO Sridhar Ramaswamy stated that the company's AI products accounted for around half of that growth acceleration, which ****** ysts took as implying that AI demand is increasing Snowflake's core data platform, instead of just adoption of standalone AI add-ons. UBS ****** yst Karl Keirstead said the figures, together with Palantir and Databricks' rapid growth, gave compelling proof of robust enterprise AI adoption.
Snowflake's beat rippled across enterprise software, with ServiceNow, Atlassian, Adobe, Intuit, and Salesforce, Inc. (NYSE:CRM) all up 3.5% to 6% on the same day, while the sector-wide iShares Expanded Tech-Software ETF rose 3%.
That Snowflake-driven spike was piled on top of a much bigger adjustment made by Salesforce, Inc. (NYSE:CRM) on its own. The company released its second-quarter fiscal 2027 results on August 26, a week before Snowflake Inc. (NYSE:SNOW), with revenue of $11.35 billion, up 11% year-over-year, with current remaining performance obligations up 14% to $33.5 billion and adjusted EPS of $5.90, exceeding the $3.27 consensus. Along with those results, Salesforce and Anthropic announced Claudeforce, an expanded partnership that initially brings Salesforce data, workflows and business logic directly into Claude through a plugin with 37 prebuilt sales skills. The companies plan additional integrations across Claude, Salesforce and Slack. That said, Salesforce recorded $2.61 billion in net gains on strategic investments during the quarter, which added $2.53 per share to non-GAAP EPS.
Taken together, the two events suggest that enterprise AI adoption can increase the value and consumption of established software platforms when AI is connected to existing corporate data and workflows

#billion #software #data #quarter

On September 10, IBEX Limited (NASDAQ:IBEX) held its fourth-quarter and full fiscal year 2026 earnings call, and the numbers backed up a message management has been building toward for months. The company posted record full-year revenue, adjusted EBITDA, and free cash flow, all while pitching itself as a business that has flipped the AI narrative in its favor rather than becoming its next casualty. For a sector that has spent the last two years bracing for automation to gut it, that is a notable claim to back with actual client wins.
Full-year revenue hit $644.1 million, up 15.4% organically, and fourth-quarter revenue reached $164.3 million, up 11.6% from a year earlier. That marked the sixth straight quarter of double-digit growth, a streak that suggests the momentum is not a one-off. HealthTech led the charge, climbing 38.5% to $114 million for the year and blowing past the $100 million target management had set for the segment, driven largely by demand from large insurance payers. Technology grew 27.4% in the quarter, while travel and logistics added 17.8%, helped by a new AI agent partnership with Philippine Airlines.
That Philippine Airlines deal is the clearest evidence that IBEX's Sierra AI partnership, formalized in January and announced publicly in May, is more than a slide in an investor deck. During the proof of concept, the AI agent handled interactions in English, Tagalog, and Taglish, hit resolution rates above 20%, and scored a 4.7 out of 5.0 on customer satisfaction, on par with human agents. A separate deployment for BJ's Wholesale pushed resolution rates above 40% and matched that same satisfaction score, beating the marks the client's prior BPO vendor had put up with human agents alone. The company added 17 new trophy logo clients across the year, and its top five clients now make up 33% of revenue, down from 36%, a sign the business is not leaning on a shrinking handful of accounts to carry it.
Not every line moved in the right direction. Fourth quarter GAAP net income slipped to $8.7 million from $9.6 million a year earlier, and diluted EPS fell to $0.59 from $0.66. Management pointed to training costs tied to all those new client wins, a temporary hit from shifting work out of nearshore centers into offshore ones, and higher fuel prices hitting utility and transportation costs, particularly offshore. Adjusted EBITDA margin for the quarter slipped to 12.3% from 13.9%, the same set of pressures showing up in the profitability line rather than just net income.

#revenue #fourth

Prince Harry might be back in the UK, but that doesn't mean he's returned to royal duties. In fact, both Harry and his father, King Charles, have made it clear that he is not a working royal and likely won't ever be again. Proof of that is that Harry was not invited to the funeral of Norway's King Harald.
William represented the British royal family and walked behind the monarch's coffin on Wednesday, September 9. He was accompanied by Princess Anne for the procession, which extended from the Royal Palace to Oslo Cathedral. Other foreign royals present included King Felipe VI and Queen Letizia of Spain, as well as King Carl XVI Gustaf and Queen Silvia of Sweden and King Frederik X and Queen Mary of Denmark.
More from StyleCaster
'Wounded' Harry Reportedly 'Blames' Charles for Devastating Business 'Withdrawal'-He Feels 'Injured'
William Reportedly 'Disturbed' by Harry's 'Vulgar' Act-It's a 'Betrayal'

#prince #harald

Democratic state parties announced Monday that they are launching an operation for the midterm elections they're calling the "New Battlefield Project," intended to recruit 10,000 volunteers to guard polling places in case armed federal officers show up.
Activists are planning mass protests if the Trump administration tries to interfere with voting or ballot counting. And legal scholars are distributing white papers advising judges what they should do if the government tries to seize ballots.
The unprecedented efforts are in response to President Donald Trump's equally unprecedented moves to interfere in this year's midterm elections, which include attempts to impose proof-of-citizenship requirements to register to vote and directing the Postal Service to play a central role in deciding which voters should get a mail ballot.
The anxious contingency planning as voting gets underway has become a marker for how fraught democracy has become in the country that once stood as an example to the world.
"We have never prepared for an election sabotage event like we have now," said Ezra Levin of the left-leaning group Indivisible.

#interfere

Interested in Johnson & Johnson? Here are five stocks we like better.
Johnson & Johnson raised its growth ambitions, forecasting 6.5% adjusted operational sales growth and 7.3% adjusted EPS growth in 2026, with revenue expected to surpass $100 billion. Executives see 2027 improving further and aim for double-digit growth by the end of the decade despite STELARA biosimilar competition.
The company plans to detail its long-term growth strategy at an enterprise review in December, highlighting new product launches, a pipeline that includes 12 proof-of-concept molecules in Phase III, and the durability of growth beyond 2030.
Capital spending is focused on Innovative Medicine and MedTech launches, including ICOTYDE, cancer treatments, and the OTTAVA robotic surgical system. J&J also expects continued momentum from its myeloma therapies, ICOTYDE's expanding coverage, and MedTech products, while using acquisitions mainly to support growth beyond the current decade.
5 Defensive Stocks to Watch as CPI and the Fed Put the Rally to the Test

#adjusted #interested

Fundstrat's Tom Lee took the Future Proof Citywide stage earlier this year with CNBC's Scott Wapner for a session that landed in the middle of a jittery tape that included geopolitical conflict, oil spiking, private credit cracking, and fresh doubts about AI spending. Not too far off where we find ourselves currently, but with an awful lot of volatility and shifting, uncertain outlooks between these six months. While their conversation was a snapshot in time, you can expect more of this kind of sharp, thoughtful ****** ysis next week.
The contrarian take of the session was oil. High crude, Lee argued, is actually constructive for U.S. equities. With the U.S. as a net exporter, our economic competitors are importers, and stalled global growth pushes investors toward growth stocks, which is about 80% of the U.S. market. On AI CapEx, he pushed back on the sticker shock, claiming roughly $700 billion a year is a fraction of the $60 trillion global labor market and small change against daily moves in gold.
Lee also made the case that software had bottomed at the time, that enterprises building their own tools inherit the maintenance burden software companies exist to carry, and that private credit is genuinely bad but not a GFC repeat, with the real fix being taking private companies public rather than pushing private product into retail portfolios. On crypto, his argument shifted from a perspective of digital gold to one of plumbing whereby Wall Street tokenizes ****** ets, and AI agents needing a settlement rail that handles fractions of a penny.
His parting advice was the oldest one in the book, dressed in new clothes: miss the 10 best days of each year and a 16% average return goes to roughly nothing. Danger and opportunity show up together. Staying invested is the perpetual drumbeat of advisors to their clients, but one that needs banging louder when markets feel much less certain.
Future Proof Festival is September 14–17 in Huntington Beach and includes four days on the boardwalk with advisors, ****** et managers, and fintechs building the modern wealth management industry. Find us at the ETF Oasis and don't miss the stellar agenda we've got lined up.

#find #session #credit #time

All eyes are on the Fed with another higher than expected reading for core inflation. Jeff Klingelhofer, CFA, Managing Director, Portfolio Manager & Senior Research **** yst, Securitized **** ets at Aristotle Pacific, talks with host Brad Roth on this episode of Behind the Ticker about why the new Fed Chair stepping into an environment of high inflation matters for investors and bonds, and what that means for how the firm is positioning their strategies that include three new ETFs, the Aristotle Core Plus Income ETF (ARCP), the Aristotle Multi-Sector Income ETF (ARMS), and the Aristotle Short Term Income ETF (SDUR).
You can also watch this conversation here or on our YouTube, as well as find it on any of your preferred podcast streaming platforms.
A non-traditional path to fixed income: Jeff Klingelhofer started at PIMCO, moved through Tokyo and London, then took an unexpected detour into a five-person hedge fund during his Chicago MBA. That experience shaped his career trajectory, from building Thornburg's taxable fixed income desk from scratch to joining Aristotle Pacific in 2024.
The relative value philosophy: Instead of chasing yield by taking more risk within a single **** et class, Klingelhofer compares opportunities across all of fixed income, including corporates, ABS, CLOs, bank loans, and more. His go-to example: in 2020, an American Airlines corporate bond and its aircraft-backed EETC priced identically, but a month later one traded at 27 cents on the dollar while the other held at 65 cent, proof that siloed desks miss cross-market mispricing.
Three ETFs, one philosophy: Aristotle Pacific's new suite of SDUR (short-term income), ARCP (core plus), and ARMS (multi-sector income) applies this relative value lens across the risk spectrum, each targeting a different level of duration and credit exposure. All three aim to outperform passive benchmarks through active security selection rather than added risk.

#jeff #etfs

The Chargers will take the field for the first time in 2026 with an opening weekend matchup against the Cardinals on deck.
Here's what Los Angeles needs to do on offense to come away with a win.
One of the biggest appeals of hiring Mike McDaniel this offseason to coordinate the offense is what it might do for Herbert, who is being lauded as a potential MVP candidate with McDaniel's system attached. Chargers fans caught a glimpse of what that could look like in the preseason game against the Rams when Herbert hit Quentin Johnston for a long-range touchdown. A full game of Herbert operating the McDaniel offense should be a thing of beauty, but both men will need to show that this marriage lives up to the hype in order for Sunday to feel like a success.
McDaniel put up wanted posters for fullback Alec Ingold and running back Keaton Mitchell in the Chargers facility before LA was able to sign both players, in addition to adding tight ends Charlie Kolar and David Njoku. Sunday will be LA's first chance to show why those players in particular make this offense hum - what sort of usage does Ingold see as a fullback? Is Kolar going to be a more well-rounded receiving threat? What does the rotation look like between Kolar, Njoku, and second-year player Oronde Gadsden II? How much will Mitchell eat into Omarion Hampton's touches? The Chargers should be looking for proof of concept in Week 1, and that will come by answering at least a few of those questions and introducing fans to some of their new contributors on offense.
An interior offensive line of left guard Kayode Awosika, rookie second-round pick center Jake Slaughter, and right guard Cole Strange isn't anything to write home about, but McDaniel has made do with seemingly substandard trios on the inside before. Nolen looked like a potential game-wrecker in limited action for Arizona last season and now returns as the cornerstone of a defensive line who will look to take advantage of what has to be LA's greatest weakness on offense. If the Chargers can keep Nolen from making a big impact by sending help towards him and getting the ball out quickly to start the game, they should be able to keep things humming on offense.

#mcdaniel #kolar

Rep. Ilhan Omar, D-Minn., gave the cold shoulder when asked to weigh in on her son's home being raided by police after his convicted felon roommate was arrested.
Minneapolis police officers found while carrying out a search warrant on August 25 multiple weapons and ammunition in the shared home of Omar's son, Adnan Hirsi, 20, and his roommate Abdulrahman Abdi, 22. The warrant was obtained after Abdi was pulled over in a routine traffic stop and was found to have no driver's license or proof of insurance.
Abdi was released and the car was impounded, but a firearm was later found. As a convicted felon, it is illegal for Abdi to possess a firearm, so the property that he shares with Abdi was raided.
Caught On Camera: Squad Dem Squirms When Pressed On Vance Doj Fraud Probe
Rep. Ilhan Omar, D-Minn., is seeking another term in Minnesota's heavily Democratic 5th Congressional District.

#found

At just 46 years old, Dino Mavrookas' career already looks more expansive than most, spanning three distinct roles: Navy SEAL, private-equity investor, and now cofounder and CEO of $9.25 defense-tech startup Saronic—proof that your first career doesn't have to be your last.
His latest career pivot came just four years ago, when Mavrookas was a senior ***** ociate at Austin-based private equity firm Vista Equity Partners. However, after half a decade in finance—likely bringing in a six-figure salary—Mavrookas began to question whether he wanted to spend the rest of his career on the same path.
"After five years, I started to look around and say, is this what I want to do for the next 20 or 30 years of my life? Like, I learned a ton about investing. I learned a ton about operating companies, but is this what I wanted my career to be? And the answer was no," Mavrookas said in a recent interview on the Sourcery podcast.
"I walked into the living room one night and I told my wife that I had to quit my job."
Mavrookas knew he wanted to start a defense-tech company, but he didn't yet know what the business would be. What he did know was that he needed to create the time and ***** e to figure it out.

#mavrookas #years #wanted #private